Overview

Effect of a Proton Pump Inhibitor on the Pharmacokinetics (PK) of Tepotinib

Status:
Completed
Trial end date:
2018-07-02
Target enrollment:
Participant gender:
Summary
This study will investigate in healthy subjects (i) the effect of omeprazole (proton pump inhibitor) co-administration on the single dose PK of tepotinib under fed conditions, and (ii) the effect of food on the single dose PK of tepotinib after co-administration of omeprazole and tepotinib. Furthermore, the study will assess the safety and tolerability of tepotinib alone and upon co-administration of omeprazole.
Phase:
Phase 1
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Treatments:
Omeprazole
Proton Pump Inhibitors
Tepotinib